3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
NIH
2
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Capecitabine
77
pembrolizumab
70
Oxaliplatin
68
Cisplatin
56
Fluorouracil
52
Paclitaxel
41
Trastuzumab
37
Nivolumab
35
Leucovorin
27
Docetaxel
27
Irinotecan
22
Ramucirumab
20
Gemcitabine
15
Bevacizumab
15
S 1 (combination)
14
Carboplatin
13
atezolizumab
12
apatinib
12
fludarabine
11
Cyclophosphamide
11
tislelizumab
10
Drug Therapy
10
Injections
8
130-nm albumin-bound paclitaxel
8
trastuzumab deruxtecan
7
durvalumab
7
Ipilimumab
7
Folfox protocol
7
Albumin-Bound Paclitaxel
7
titanium silicide
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Stomach Neoplasms
×
Interleukin-12
×
Clear all
NCT02960594
2018-11-19
TRT-001
Inovio Pharmaceuticals
Phase 1
Completed
93 enrolled